Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug964 | DAS181 COVID-19 Wiki | 1.00 |
| drug965 | DAS181 OL Wiki | 1.00 |
| drug963 | DAS181 Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018184 | Paramyxoviridae Infections NIH | 0.58 |
| D012141 | Respiratory Tract Infections NIH | 0.18 |
| D003141 | Communicable Diseases NIH | 0.08 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.19 |
Navigate: Correlations HPO
There is one clinical trial.
This is an open-label, randomized, controlled study in hospitalized subjects with confirmed SARS-CoV-2.
Description: Time to treatment failure during the 28-day treatment period. Treatment failure is defined as additional or alternative treatment required, or intubation and invasive ventilation, or transfer to intensive care unit, or death.
Measure: Evaluation of EPA-FFA efficacy compared to standard of care Time: 28 daysDescription: Time to (in days) and number of days with oxygen saturation >95% without oxygen inhalation during the 28-day treatment period
Measure: Increase in oxygen saturation Time: 28 daysDescription: Time to (in days) and number of days with PaO2/FiO2 >300mmHg without oxygen inhalation during the 28-day treatment period
Measure: PaO2/FiO2 >300mmHg increase Time: 28 daysDescription: Change in IL-6 level during the 28-day treatment period
Measure: Reduction of IL-6 Time: 28 daysDescription: To determine whether EPA-FFA gastro-resistant capsules decreases mortality rate during the study.
Measure: Mortality rate reduction Time: throughout the study, about 3 monthsDescription: To determine whether EPA-FFA gastro-resistant capsules decreases ICU days during the study.
Measure: Reduction in ICU stays Time: throughout the study, about 3 monthsDescription: To determine whether EPA-FFA gastro-resistant capsules decreases hospitalisation days during the study
Measure: Reducing hospitalisation days Time: throughout the study, about 3 monthsDescription: To determine whether EPA-FFA gastro-resistant capsules decreases the need for invasive mechanical ventilation during the study
Measure: reduction in need for mechanical ventilation Time: throughout the study, about 3 monthsDescription: Time to (in days) and number of days with fever normalization < 36.6°C armpit, < 37.2°C oral, < 37.8°C rectal, during the 28-day treatment period
Measure: Fever reduction Time: 28 daysDescription: To evaluate the safety of EPA-FFA gastro-resistant capsules in the treatment of COVID-19 (SARS-CoV-2) by assessing subjects clinical lab parameters and vital signs, and the number and proportion of subjects with AEs.
Measure: Safety - Vitals, AEs and Clinical lab parameters Time: throughout the study, about 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports